Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) belong to a class of compounds that reduce blood glucose and energy intake by simulating actions of endogenous incretin hormone GLP-1 after it is released by the gut following food consumption. They are used to treat type 2 diabetes mellitus (T...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhi Dong Zhou, Lingxiao Yi, Karolina Popławska-Domaszewicz, Kallol Ray Chaudhuri, Joseph Jankovic, Eng King Tan
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Series:	Pharmacological Research
Subjects:	Glucagon-like peptide-1 GLP-1 receptor agonists Neurodegenerative diseases Alzheimer’s disease Parkinsons' disease Type 2 diabetes mellitus
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661825001951
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence
by: Panagiotis Stachteas, et al.
Published: (2025-07-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
by: Ping-Tao Tseng, et al.
Published: (2025-04-01)

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
by: Obieda Altobaishat, et al.
Published: (2025-12-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
by: Ansel Shao Pin Tang, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors
by: Valeria Grancini, et al.
Published: (2025-05-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
by: Michał Stasiak, et al.
Published: (2025-06-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis
by: Yan Xu, et al.
Published: (2025-04-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

Multiomics insight into the role of glucagon‐like peptide‐1 receptor agonists in heart failure
by: Yuhang Tao, et al.
Published: (2025-08-01)

Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens
by: Fernando Lizcano, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
by: Yu-Xuan Yao, et al.
Published: (2025-12-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes
by: James Goodman, et al.
Published: (2025-07-01)

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia
by: Luigi Vetrugno, et al.
Published: (2025-03-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants
by: Amirah Alhowiti, et al.
Published: (2025-07-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trialResearch in context
by: Mads Gamborg, et al.
Published: (2025-08-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)